Nessan Bermingham Net Worth & Insider Trades
Nessan Bermingham - President & CEO, Intellia Therapeutics, Inc
What is Nessan Bermingham's Net Worth?
The current estimated net worth of Intellia Therapeutics, Inc's President & CEO, Nessan Bermingham, is estimated to be about $43M . Nessan Bermingham owns about 458,250 units of Intellia Therapeutics, Inc common stock. In the last year at Intellia Therapeutics, Inc, Nessan Bermingham has sold an estimated value of $7M worth.
What is Nessan Bermingham's Past Insider Trading?
Nessan Bermingham's largest sale order was 336,783 units , worth over $7M on December 8, 2017. In total, Nessan Bermingham has made about 5 transactions over a year of their time at Intellia Therapeutics, Inc. Nessan Bermingham usually trades in December, with the busiest year in 2017.
Nessan Bermingham
Date Range: All Time
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||
What is Nessan Bermingham's' Mailing Address?
- Mailing address is 890 Winter Street Waltham MA 02451 MA
Intellia Therapeutics, Inc Executive Compensation
Name |
Year
|
Salary
|
Bonus
|
Option Awards
|
Stock Awards
|
Other Compensation
|
Total
|
|---|---|---|---|---|---|---|---|
| John M. Leonard, M.D. | 2020 | $580,000 | $319,000 | $2,722,890 | - | $13,786 | $3,635,676 |
| John M. Leonard, M.D. | 2019 | $559,200 | $307,560 | - | - | $37,026 | $903,786 |
| John M. Leonard, M.D. | 2018 | $550,000 | $302,500 | $7,818,005 | $1,011,713 | $26,112 | $9,708,330 |
| Glenn G. Goddard | 2020 | $407,000 | $146,520 | $1,001,063 | - | $8,928 | $1,563,511 |
| Glenn G. Goddard | 2019 | $383,000 | $153,200 | - | - | $5,644 | $541,844 |
| Glenn G. Goddard | 2018 | $67,718 | $51,652 | $1,896,825 | - | $218 | $2,016,413 |
| David Lebwohl, M.D. | 2020 | $298,378 | $228,000 | $1,549,720 | - | $2,690 | $2,078,788 |
| Andrew D. Schiermeier, Ph.D. | 2020 | $455,400 | $173,052 | $1,081,148 | - | $8,928 | $1,718,528 |
| Andrew D. Schiermeier, Ph.D. | 2019 | $440,000 | $167,200 | $611,897 | - | $8,778 | $1,227,875 |
| Andrew D. Schiermeier, Ph.D. | 2018 | $408,934 | $182,600 | $2,028,554 | $295,550 | $9,668 | $2,925,306 |
| Laura Sepp-Lorenzino, Ph.D. | 2020 | $420,000 | $184,800 | $1,081,148 | - | $4,578 | $1,690,526 |
| Laura Sepp-Lorenzino, Ph.D. | 2019 | $239,487 | $204,086 | $1,318,695 | - | $221 | $1,762,489 |
| No matching records found | |||||||
Source: https://www.sec.gov/Archives/edgar/data/1652130/000156459021021413/ntla-def14a_20210623.htm
What are Intellia Therapeutics, Inc's Past Insider Trades?
Intellia Therapeutics, Inc's most recent insider trade came on March 3, 2023 by James Basta who sold 1,088 units worth $47.74K . In the last 7 years, insiders at Intellia Therapeutics, Inc have sold an estimated value of $307.06M and bought an estimated value of $44M worth of shares. Insider trading is most common in May, with the busiest year in 2021. The most active traders at the company are John Leonard, President and CEO, Francois Jean Formela, Director, and Jose Rivera, EVP .
Intellia Therapeutics, Inc. Insider Trades
Date Range: All Time
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||